Introduction {#s1}
============

Nitric Oxide (NO) is a small gaseous molecule recognized as a ubiquitous intercellular messenger modulating crucial functions including blood flow, platelet aggregation, and neural activity (Moncada, [@B73]).

This molecule is synthesized from L-arginine by three isoforms of Nitric Oxide Synthases (NOSs) and all of them (nNOS, Inos, and eNOS) concur to regulate the autonomic nervous system.

NO exerts its activity essentially by stimulating soluble Guanylyl Cyclase (GC) to increase the levels of the second messenger cGMP, which in turn modulates the performance of adrenergic receptors (ARs).

Recently, many studies highlighted an important role in the regulation of the vasomotor tone of the β-adrenoreceptor subtype β~3~, which, differently from the classical β~1~- and β~2~-ARs, induces a negative inotropism in the human heart (Balligand, [@B2]; Salazar et al., [@B96]).

NO effects depend, among others, on NO concentration, compartmentalization of NOS enzymes and local redox conditions of cells and tissues and, to date, many evidences collected by both *in vivo* and *in vitro* experiments suggest a crosstalk between NO, ARs and oxidative stress in the control of endothelium homeostasis, and in the sympathetic regulation of the vascular tone (Graves and Poston, [@B46]; Lembo et al., [@B62]; Selemidis et al., [@B100]).

The NO pathway is directly implicated in the development and progression of diseases such as hypertension and heart failure (HF) and, recently, this molecule has been considered a promising target to develop new clinical strategies against cardiovascular pathologies (Levy et al., [@B64]).

In addition, it is worth noting that some studies showed that polymorphisms in genes encoding for ARs and NOS enzymes could influence aging, onset and progression of cardiovascular diseases (CVD), and response to therapy (Jáchymová et al., [@B52]; Garovic et al., [@B45]).

The main focus of this review is the mechanisms underlying the interconnection between β-ARs and NO in the cardiovascular system, and the therapeutic potential of new discoveries in this field.

NO modulates vasomotor tone by interfering with sympathetic autonomic nervous system
====================================================================================

In 1980s the Endothelium-Derived Relaxing Factor (EDRF), discovered by Moncada, was identified as NO (Hutchinson et al., [@B50]; Palmer et al., [@B82]) and, from that moment, several studies shed light on a countless number of important roles played by this molecule which was proclaimed Science\'s "Molecule of the Year 1992" (Nathan, [@B77], [@B78]; Bredt and Snyder, [@B12]).

Since its discovery, it was clear that NO acts as a key modulator of the vascular tone and that its vascular effects are generally mediated by Guanosine 3′,5′-cyclic MonoPhosphate (cGMP) through the activation of guanylate cyclase. In fact, several experiments using NO donors and/or cGMP analogs have shown that cGMP is a critical and multifunctional second messenger that mediates several functions in cardiac and vascular tissues as well as the etiology and pathophysiology of cardiovascular disorders (Tulis, [@B110]). Both neurotransmitters and hormones released from autonomic nervous system cooperate to preserve the balance between vasoconstriction and vasorelaxation and to control cardiac muscle cells function, and it is now generally accepted that NO exerts a critical role in this context. Balligand et al., which investigated the effects of NOS inhibitors in isolated neonatal and adult rat ventricular myocytes, exposed to either muscarinic or adrenergic agonists, concluded that the physiological response of the cells to both muscarinic cholinergic and β-adrenergic stimulation is mediated, at least in part, by NO production (Balligand et al., [@B5]).

Cardiovascular homeostasis is regulated by NO produced by all three NOS isoforms. Several studies demonstrated, both *in vivo* (Schwarz et al., [@B99]) and *in vitro* (Horackova et al., [@B49]), that NO produced by neuronal NOS (nNOS) controls catecholamines release in response to electrical adrenergic nerve stimulation. This is very important also in consideration that elevated levels of cathecolamines are associated to several pathologic conditions such as HF (Rengo et al., [@B91]).

The inducible NO Synthase (iNOS) has been also involved in several aspects of cardiovascular biology such as the defence against intracellular microorganisms (Balligand and Cannon, [@B4]).

Moreover, endothelial cells express, in heart and vessels of a variety of species including humans, endothelial NO Synthase (eNOS), an isoform that is activated to produce NO in response to stimulation of both adrenergic and muscarinic cholinergic receptors in cardiac myocytes (Balligand et al., [@B6]).

Many studies demonstrated that vascular endothelial cells might also express β-adrenoceptors (Buxton et al., [@B15]; Molenaar et al., [@B72]), thus supporting the idea that the endothelium might control or facilitate β-adrenergic effects on the vessels. The main mechanism leading to increased eNOS activity in endothelial cells is calcium-dependent (Wu, [@B116]), but phosphorylation at several loci of the NOS proteins has been recognized as an additional pathway to induce both activation and inhibition of eNOS activity (Bauer et al., [@B8]; Fleming and Busse, [@B42]).

Both *in vivo* and *in vitro* studies suggested that the vascular endothelium might mediate β-adrenergic vasorelaxation, though not all the results presented are in agreement with each other. For instance, it was observed that rat mesenteric resistance arteries can be relaxed by NO release upon β~1~-adrenoreceptor stimulation (Graves and Poston, [@B46]). Priest et al. showed an involvement of NO in β-mediated vasorelaxation in large but not in small rat arteries suggesting a role of NO strictly dependent on the vascular area (Priest et al., [@B83]).

Ferro et al. verified that the stimulation of β~2~-adrenoreceptors led to an increase in NO, which in turn caused relaxation of Human Umbilical Vein Endothelial Cells (HUVEC). In this study, the authors provided also a comparison between β-adrenoreceptor function measured in HUVEC and the response to β-adrenergic stimuli in intact vessels, showing the importance of endothelium in maintaining vascular homeostasis (Ferro et al., [@B41]). In addition, Lembo et al. suggested the existence of an endothelium NO component essential for the insulin modulation of α~2~- and β-adrenergic vascular responses. An impairment of the equilibrium between endothelial and vascular smooth muscle adrenergic signaling could contribute to the increase of vascular resistance, a pivotal phenotypical trait of essential hypertension (Lembo et al., [@B61]).

Role of β~3~-adrenoceptor
=========================

Emerging evidences highlighted a role played by a third β-adrenoreceptor subtype (β~3~), traditionally known as a modulator of lipolysis in adipose tissue, as a regulator of the vasomotor tone in conjunction with β~1~- and β~2~-ARs (Trochu et al., [@B108]).

The involvement of a β-receptor, other than classical β~1~- and β~2~-ARs, has been suggested in several experiments which used a different concentration of non-selective β-blockers (Clark and Bertholet, [@B24]; Doggrell, [@B37]; Oriowo, [@B80]) and preferential β~3~-AR agonists (Berlan et al., [@B10]).

It is now widely accepted that the vasoactive effects dependent on the stimulation of β-ARs are strongly associated with NO production and activation (Trochu et al., [@B108]).

Recently, many investigations focused on β~3~-ARs, which are detected in human endothelial cells and cardiac myocytes of the human heart. These receptors subtypes are highly expressed in the atrium and, in contrast to β~1~- and β~2~-ARs, are responsible of a negative cardiac inotropic effect (Moniotte et al., [@B74]). Moreover, on the basis of differential expression of β~3~-ARs in the human myocardium chambers, Brixius et al. found that eNOS is activated by β~3~-AR predominantly via phosphorylation in the left ventricle and through a translocation process in the atrium (Brixius et al., [@B13]).

The link between β~3~ AR, eNOS and vasodilation mechanism was demonstrated also in *in vivo* models; recent advances in the field were achieved by using nebivolol, a β~1~-blocker. Dessy et al. verified that nebivolol dilates human and rodent coronary resistance microarteries, and showed that this effect is sensitive to NOS inhibition and is hampered in β~3~-adrenoreceptor-deficient mice. Moreover, the authors showed proangiogenic properties of nebivolol, which are dependent by both eNOS and β~3~-adrenoreceptors (Dessy et al., [@B35]).

Interestingly, β~3~-AR is upregulated during cardiomyophaties in humans and this characteristic, together with its peculiar differential expression in the human myocardium, makes it an attractive target for the development of new clinical strategies against CVD (Moniotte et al., [@B74]).

Many studies investigated the involvement of β~3~-AR in the onset and progression of cardiovascular clinical conditions both in animal and human models, and it seems conceivable that the stimulation of β~3~-AR leads to NO-mediated protective effects in vascular beds (Dessy et al., [@B34], [@B35]). In addition, in case of neurohormonal stress, β~3~-ARs expressed in the endothelium promote coronary perfusion through their vasodilator and pro-angiogenic effects (Balligand, [@B3]).

Recently, a randomized trial, named SENIORS (Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with HF) was performed to investigate the effects of nebivolol on the ejection fraction in aged patients (≥70 years).

Notably, nebivolol possesses vasodilator ancillary properties, probably mediated by the endothelial L-arginine NO pathway. In particular, it was demonstrated that the favorable hemodynamic profile of nebivolol, including the lowering of blood pressure, is partially due to NO release from endothelial cells (Maffei et al., [@B69]). In addition, thanks to its antioxidant activity, nebivolol prevents the detrimental effect on NO bioavailability associated to oxidative stress (Ignarro, [@B51]).

To date, preclinical and clinical data confirm that NO benefits might due to β~3~-ARs overexpression. However, caution should be used, as the long term effects of β~3~-ARs agonists on left ventricular function in the heart have not yet been fully evaluated.

Furthermore, many studies investigated the impact of life-style changes and non-pharmacological interventions on the cardiovascular homeostasis, and convincing evidences showed a favorable role exerted by diet and caloric restriction. For example, Nisoli et al. demonstrated that caloric restriction leads to enhanced mitochondrial biogenesis, at least in part, by inducing the activation of eNOS (Nisoli et al., [@B79]), and Cerqueira et al. observed a time-dependent increase of eNOS activation and NO bioavailability in vascular cells conditioned with serum of caloric restricted rats (Cerqueira et al., [@B22]).

Also exercise training (ET), currently used in cardiac rehabilitation (CR) programs, was recognized to improve some cardiovascular outcomes by inducing NO levels to increase, even if this strongly depends on both the type and intensity of exercise (Conti et al., [@B27], [@B29]).

Jenkins et al. suggested that a regular physical activity in combination with dietary restriction positively influences, in a NO-dependent manner, the expression of β-AR and natriuretic peptide receptors in adipose tissues of obese rats (Jenkins et al., [@B54]). In addition, Calvert et al. showed that an ET-dependent stimulation of β~3~-ARs is useful to counteract myocardial ischemia-reperfusion injury by increasing NO signaling (Calvert et al., [@B16]).

These and many other studies remarked a crucial role played by NO in cardiovascular homeostasis.

Adrenoreceptors stimulation, vascular redox state and nitric oxide bioavailability
==================================================================================

Experimental *in vivo* and *in vitro* evidences suggest a crosstalk between NO, adrenoreceptors and oxidative stress in the function and adaptation of endothelium, and in the sympathetic control of the vascular tone.

Excess of ROS and/or failure of antioxidant endogenous defense may result in ROS-mediated reduction of NO bioavailability in the cells. The influence of oxidative stress on the pathway of NO biosynthesis has been extensively investigated and its effects, due to either direct quenching or impaired synthesis of NO, strongly affect the vasodilation mechanism (Förstermann and Sessa, [@B43]).

It has been showed that β~2~-ARs excitation increases cellular uptake of L-arginine, an eNOS substrate, and eNOS activity can be specifically stimulated by these AR subtypes in human endothelial cells. Moreover, β~2~-ARs stimulation hyperpolarizes cellular membrane, and L-NAME, a well known NOS inhibitor, may hinder this process (Wyatt et al., [@B117]; Queen et al., [@B85]).

*In vitro* experiments using endothelial cells showed an increase of β~2~-ARs-mediated eNOS phosphorylation at serine-1177, highlighting a β~2~-AR-dependent NOS activation through a Ca^2+^ insensitive mechanism (Dimmeler et al., [@B36]; Queen et al., [@B85]; Cannavo et al., [@B17],[@B18]).

Recently, Davel et al. investigated the role of oxidative stress in sympathetic-dependent contractility of human endothelium. The authors observed an increase of contractile response in β~2~-knockout (KO) mice and showed that the loss of function of these receptors in vascular tissue can induce ROS-mediated NO impairment. Administration of α1-agonist phenylephrine in the aorta of β~2~-KO mice suggested a key role played by NO in the control of vasomotor tone. In fact, the reduction of basal content of NO enhanced the vasoconstriction rate in the aorta of mice deficient for β~2~-adrenoreceptors. These experiments suggested that β~2~-ARs in vascular tissues are necessary to maintain basal levels of NO, thus concurring to modulate vascular homeostasis (Davel et al., [@B31]). The lack of functional β~2~-receptors led to an increase of oxidative stress in the aorta of β~2~-KO mice, and a treatment with antioxidant superoxide dismutase was sufficient to limit the vasoconstrictor response to phenylephrine. These results suggest the existence of an important link between adrenergic pathway, NO bioavailability and oxidative stress.

Indeed, several studies have showed antioxidant properties of NO, confirming the role of this molecule to counteract superoxide anions production by NADPH oxidase, the major source of superoxide in blood vessels. Several stimuli, such as oscillatory shear stress, hyperglycemia and lipid peroxidation could cause impairment in the NADPH oxidase system that, in turn, produces accumulation of ROS and reduction of NO content (Vecchione et al., [@B113]).

Selemidis et al. showed that prolonged exposure of human endothelial cells to NO donors, such as long-acting nitrates, induced a significant decrease of ROS via inhibition of p47phox NADPH oxidase subunit (Selemidis et al., [@B100]). By reducing the oxidative stress, NO donors may exert several vascular protective effects and they could be used not only for a symptomatic treatment, but also to prevent and eventually revert many aspects of CVD.

NO antioxidant properties and the ability of NO donors to counteract NADPH oxidase-dependent superoxide production are well established. However, ROS other than superoxide anions could play a role in determining redox state imbalance and the resulting detrimental effects on NO biosynthesis. Indeed, cardiovascular side effects of drugs, such as acetylsalicylic acid and other ciclooxygenase inhibitors may be due to their influence on oxidative stress hallmarks in coronary circulation, and coronary perfusion. In this context, it was suggested that those effects can be modulated by inhibition of NOS following the increase of superoxide, hydrogen peroxide and lipid peroxidation (Barudzic et al., [@B7]).

Further studies in the field of the antioxidant effect of adrenergic-dependent NO modulation could be essential to develop new drugs and clinical strategies to modulate oxidative stress in vascular diseases.

Nitric oxide and cardiovascular diseases
========================================

Given its crucial role in the autonomic nervous system control, the NO pathway is directly implicated in diseases, such as hypertension and HF.

The generation of NO in the vascular endothelium ensures the maintenance of the vasodilator tone that is required for the regulation of blood flow and pressure.

Moreover, NO bioavailability plays an important role in the pathophysiology of CVD and its reduction in endothelial cells is strictly associated to endothelial dysfunction and hypertension (Lyons, [@B68]; Yetik-Anacak and Catravas, [@B119]).

The link between endothelial dysfunction and vascular diseases is well established (Rengo et al., [@B88]). It is known, for instance, that impairment of endothelial function precedes atherosclerosis (Brush et al., [@B14]).

Stimulation of endothelial β-adrenoreceptors improves eNOS-derived NO production. The importance of such strong molecular interconnection has been recently demonstrated in several studies on nebivolol conducted in animals and in humans. Nebivolol is a third generation β-blocker used in the treatment of hypertension which induces vasodilation by increasing NO production.

Nebivolol has a distinctive profile among β-blockers, with the greatest selectivity for cardiac β~1~-ARs and the highest β~1~-/β~2~-selectivity compared with other β-blockers, and no effect on α-receptors. Moreover, nebivolol could enhance NO release and promote neoangiogenesis in cardiac tissue via stimulation of β~3~-ARs, thus reducing heart rate and blood pressure and improving systolic and diastolic function (Toblli et al., [@B107]).

Many studies underlined the importance of NO in the vasorelaxation mechanism of nebivolol in humans suggesting the occurrence of an additional vascular protection in hypertension. For instance, Cockcroft et al. investigated the effects of nebivolol on human forearm and demonstrated that the drug induced a potent vasodilation hampered by NO inhibitors, such as L-NAME (Cockcroft et al., [@B25]). Moreover, by comparing the effects of nebivolol and atenolol, another β~1~-antagonist, on the endothelial function of hypertensive patients, Tzemos et al. showed that nebivolol, differently from atenolol, was able to lower blood pressure with a concomitant reversing action on endothelial dysfunction (Tzemos et al., [@B111]).

The mechanism by which nebivolol acts on NO bioactivity is still unclear, but it is conceivable that the drug increases intracellular free calcium concentration by activating phospholipase C.

Studies suggested that the NO-mediated vascular effects of nebivolol may be explained considering a pharmacological cross-reactivity between serotonin 5-HT~1~ receptor and β-ARs (Fargin et al., [@B38]).

In addition, nebivolol exerts systemic antioxidative properties and this effect was hypothesized as an additional factor for increasing NO bioavailability. For example, nebivolol and atenolol similarly reduced blood pressure values in hypertensive patients, but oxidative stress markers, such as LDL hydroperoxides, 8-isoprostanes, ox-LDL were significantly improved only in patients treated with nebivolol (Troost et al., [@B109]; Fratta Pasini et al., [@B44]; Wojciechowski and Papademetriou, [@B115]).

The antioxidative property of nebivolol concurs to consider it as an optimal therapeutic presidium. In fact it was demonstrated that permanent β-ARs stimulation, typically observed during CVD, could induce an over-expression and an activation of eNOS which in turn lead to oxidative stress through superoxide anion generation and a paradoxically consequent decrease of NO bioavailability (Davel et al., [@B32]).

HF is another disease in which the NO pathway is recognized to have a crucial role. It is a very complex pathology characterized by cardiovascular dysfunction and also by diminished vascular NO bioavailability (Recchia et al., [@B86]; Sun et al., [@B102]; Wiemer et al., [@B114]; Rengo et al., [@B93]).

By using down and up-regulation of all types of human NOS genes in genetically modified mice, the involvement of NO in the pathogenesis of HF has been largely investigated and many experimental studies have demonstrated that eNOS isoform plays a protective role in HF.

For example, Janssens et al. showed that overexpression of eNOS enzyme preserves cardiac function and limits cardiac remodeling in transgenic mice over expressing human eNOS enzyme (Janssens et al., [@B53]).

Moreover, Jones et al. demonstrated that mice over expressing eNOS displayed reduction in pulmonary edema and increase in survival without differences in ventricular morphology and function, proposing that eNOS-derived NO might exert its beneficial role by decreasing vascular resistance (Jones et al., [@B56]).

Vice versa, eNOS deficient mice develop severe cardiac dysfunction and remodeling after myocardial infarction (MI).

Scherrer-Crosbie et al. studied the impact of eNOS in left ventricular remodeling after MI in eNOS- KO mice, concluding that eNOS has a key role in limiting cardiac dysfunction and remodeling, in part by decreasing myocyte hypertrophy in the remote myocardium (Scherrer-Crosbie et al., [@B98]; Cannavo et al., [@B17]).

The modulation of renin-angiotensin-aldosterone axis and adrenergic system are key elements in the therapy of several pathologies, including Alzheimer Disease (Femminella et al., [@B39]) and CVD, such as coronary artery diseases and HF (Marciano et al., [@B70]; Rengo et al., [@B92], [@B89]).

It has been reported that NO is involved in beneficial effects of drugs, including statins, Angiotensin Converting Enzyme inhibitors (ACE-I), Angiotensin II Type 1 receptor blockers (ARBs) and β-blockers.

Statin therapy significantly enhances NO bioavailability in endothelial cells and exert beneficial effects in several molecular aspects of the MI, including neovascularization, LV dysfunction, interstitial fibrosis, remodeling and survival (Landmesser et al., [@B58]).

Both ACE-I and ARBs generate cardioprotective effects in mice with post-ischemic HF by improving left ventricular function and attenuating fibrosis and hypertrophy (Cavasin et al., [@B21]). It was demonstrated that in eNOS-KO mice with HF the beneficial effects of these drugs were abolished, suggesting that NO is a key regulator of the ACE-I and ARBs effects (Liu et al., [@B67]).

Moreover, the treatment with β-blockers improves LV systolic function and produces positive cardiac remodeling (Colucci et al., [@B26]).

In particular, recent studies demonstrated that the third generation β-blockers possess important additional properties besides inhibiting β-adrenoceptors. Among them, nebivolol and carvedilol enhance the bioavailability of NO by both inducing endothelial NO synthesis and preventing free radicals-mediated NO inactivation. Therefore, these drugs show advantages compared to the conventional β-antagonists (Vanhoutte and Gao, [@B112]).

Several studies indicated carvedilol, in addition to conventional therapy, as the preferred β-blocker in the treatment of chronic HF.

Packer et al. performed a double-blind, placebo-controlled study in 1094 patients with chronic HF, demonstrating that carvedilol considerably reduced hospitalization and mortality rates for cardiovascular causes (Packer et al., [@B81]).

Moreover, combined results of studies in the US Carvedilol HF Trials Program revealed that mortality was significantly lower in carvedilol than in placebo recipients (Keating and Jarvis, [@B57]).

Nebivolol, endowed with a significant NO-associated vasodilating effect, did not provide the same results. SENIORS trial on nebivolol effects in elderly patients with HF displayed a reduction in cardiovascular mortality, but the US Food and Drug Administration did not approve this drug for the treatment of HF because the improvement in the systolic function of patients treated with nebivolol was not as substantial as with other β-blockers (Nair et al., [@B76]).

There is now compelling evidence that reduced NO bioavailability due to sympathetic hyperactivity is the major contributor to endothelial dysfunction. Thus, the effects on endothelial dysfunction of the last generated vasodilating β-antagonists might have important clinical implications, particularly in patients with resistant hypertension and possibly in the treatment of HF.

Exercise training improves nitric oxide function
================================================

ET influences cardiovascular function and endothelial homeostasis and it is recommended to treat age-associated disorders and CVD (Leosco et al., [@B63]; Rengo et al., [@B90]; Conti et al., [@B28]).

ET improves the efficiency of the endogenous antioxidant system and reduces cellular oxidation rate through the stimulation of several molecular pathways (Rinaldi et al., [@B94]). Oxidants, and ROS, more particularly, play an important role in several physiological processes, but their overproduction is responsible for the generation of oxidative stress, that may in turn directly or indirectly damage cellular constituents, including DNA, proteins, and lipids (Ferrara et al., [@B40]; Conti et al., [@B29]).

It has been demonstrated that ET contributes to maintain the balance between ROS and antioxidant activity (Corbi et al., [@B30]), thus preventing oxidative stress, which is present in all stages of both vascular and non-vascular diseases (Carrizzo et al., [@B19]; Puca et al., [@B84]).

One of the main beneficial effects of ET on the cardiovascular system is related to its ability to enhance NO production and release.

Yang et al. demonstrated that ET induces an increase of blood flow in collateral vessels of ischemic muscles and that NO inhibition abolished this effect. The authors suggested that one of the vascular adaptations induced by ET is an increase of the NO-mediated actions, which eventually culminate in the improvement of the endothelial function (Yang et al., [@B118]).

The endothelial function, strongly influenced by NO, may improve after exercise both in animal models and in humans; several studies in both healthy subjects and patients with impaired NO-related vasorelaxation remarked ET ability to improve vascular structure and function and endothelial homeostasis (Green et al., [@B47]).

Endothelial dysfunction play a fundamental role both in the onset and progression of CVD and it has been suggested that decreased NO bioavailability could definitely favors the proatherogenic endothelial cell phenotype.

Numerous studies have underlined a fundamental role played by endothelial dysfunction in both onset and progression of CVD and it has been suggested that decreased NO bioavailability could definitely favors the proatherogenic endothelial cell phenotype (Stary et al., [@B101]; Libby et al., [@B65]; Taimeh et al., [@B103]). CVD progression can be slowed, stopped, or even reversed by life-style interventions, including regular physical activity and these effects are often associated with an increase in NO bioavailability and NO metabolites (Rush et al., [@B95]; Carrizzo et al., [@B20]).

Exercise-based CR is now considered a valid therapeutic approach against CVD since it reduces morbidity and mortality. Exercise benefit depends almost in part on the exercise-based increase of NO generation, which in turn improves the endothelial function (Linke et al., [@B66]).

Laurent et al. investigated the effects of water-based exercises in patients with stable chronic HF or coronary artery disease, and found that this type of CR was effective in increasing the basal level of plasma nitrates. Such modification may be related to an improvement of the endothelial function and may be of significance for patients\' health (Laurent et al., [@B59]).

In recent years evidences about the relationship among ET, adrenergic system and NO, have been accumulating. Calvert et al. clearly demonstrated that exercise protects the heart by stimulating β~3~-ARs and increasing cardiac storage of NO metabolites. The authors observed an increase of NO generation and of cardiac nitrite and nitrosothiol levels in exercised mice. In addition, they remarked a critical role played by β~3~-ARs in regulating the phosphorylation (activation) of eNOS and the generation of NO in response to exercise (Calvert et al., [@B16]).

Due to its short half-life, it is very difficult to assess NO endothelial production in humans and all NO bioassays, albeit undoubtedly representing a practical surrogate to measure endothelial function *in vivo*, show some relevant limitations (Green et al., [@B47]).

As a consequence, novel strategies to unravel the molecular mechanisms influenced by NO are required. In this context, ET could be for example considered as a practical indirect approach to study NO effects in the endothelial cells (Conti et al., [@B29]).

Nitric oxide syntases and adrenoreceptors genetic variability
=============================================================

Extensive evidence has been recently accumulated that polymorphisms in genes encoding for ARs and NO synthase enzymes might influence aging, onset and progression of CVD and therapy response.

Montesanto et al., for instance, investigated the genetic variability linked to the three enzymatic isoforms of NO synthase (nNOS, iNOS and eNOS), and observed that genetic variants of NOS genes influenced both aging phenotypes and longevity in humans. The Authors verified the presence of a correlation between nNOS and iNOS polymorphisms and longevity from one side, and between nNOS and eNOS variants with the presence, respectively, of depression symptoms and disability from the other (Montesanto et al., [@B75]).

In addition, increasing evidence suggests that genetic polymorphisms are responsible for different cardiovascular outcomes following the use of antihypertensive drugs. Jáchymová et al. analysed the common polymorphism Glu298Asp, located in the eNOS gene, in a group of patients with hypertension and in age-matched healthy subjects. They found that this polymorphism was associated with an insufficient response of patients to conventional therapy, thus suggesting that this genetic variant may concur to the pathogenesis of essential hypertension (Jáchymová et al., [@B52]).

Zhang et al. studied several eNOS polymorphisms, highlighting a significative correlation between the presence of these variants, coronary heart diseases (CHD) and HF. In particular, this study showed that patients bearing minor allele of −690 C \> T polymorphism had higher risk in CHD and minor allele carriers for −922 A \> G variant had higher risk in HF.

Moreover, a genotype-dependent variability in the therapy response of patients randomized to the amlodipine or to the lisinopril and clorthalidone treatments was described (Zhang et al., [@B120]). Indeed, minor allele carriers treated with amlodipine showed better outcomes, when compared exclusively to those treated with lisinopril, including changes in systolic and diastolic blood pressure. These pharmacogenetic data suggested that eNOS genotyping might be useful to select the most effective and safe treatment to obtain the best individual therapy response.

Previous studies have suggested that eNOS Glu298Asp polymorphism could influence NO synthesis through the expression of a protein with different susceptibility to cleavage (Tesauro et al., [@B105]) and the same variant has been correlated with endothelial function (Savvidou et al., [@B97]; Leeson et al., [@B60]). These results, together with other epidemiological data, suggested that eNOS polymorphisms, other than the Glu298Asp, could play a role in influencing the onset and progression of vascular diseases, including CHD, HF and hypertension (Benjafield and Morris, [@B9]).

Besides the pharmacogenetic effect linked to conventional drug therapies, it was showed that Glu298Asp eNOS gene polymorphism might interact with environmental and dietary factors, such as smoking and n-3 fatty acid, influencing endothelial function (Leeson et al., [@B60]).

In addition, also ET-associated antihypertensive effects have been reported to vary on the basis of the individual genetic background. It is worth to note that a polymorphism (−786 T \> C) in the promoter region of the eNOS gene was indicated as an influencing factor of exercise beneficial effects (Augeri et al., [@B1]).

Some studies suggested that changes in NO synthesis contribute to a vasodilator response variability to β~2~ agonists. It was observed that forearm blood flow response to isoproterenol is impaired in men with hypercholesterolemia, a condition associated with dysfunctional NO activity (Chowienczyk et al., [@B23]). Moreover, the β-adrenergic vasorelaxation in the human forearm is reduced by N-monomethyl-l-arginine (L-NMMA), an inhibitor of nitric oxide synthase, confirming the crucial role played by NO in the sympathetic regulation of vascular tone (Dawes et al., [@B33]).

Several polymorphisms located in the gene encoding β~2~-receptors have been correlated to the difference in the expression, coupling and agonist regulation of these receptors. Polymorphisms affecting amino acids 16, 27, and 164 are the most common genetic variants and, for example, the Arg16Gly is known to predispose to agonist-induced down-regulation and desensitization of the receptors, probably concurring to the pathogenesis of asthma severity (Green et al., [@B48]; Reihsaus et al., [@B87]).

To confirm the involvement of the NO pathway in the β~2~-adrenoreceptor-dependent vasodilation control, Garovic et al. showed that the forearm blood flow response to isoproterenol was greater in Gly 16 then in Arg 16 homozygotes and that response was inhibited by L-NMMA (Garovic et al., [@B45]).

To date, many authors reported that adrenoreceptor (in particular, β~2~-receptors) polymorphisms are strongly associated to cardiovascular outcomes, including blood pressure, and to predisposition (Timmermann et al., [@B106]; Bray et al., [@B11]) and treatment (Johnson and Terra, [@B55]; McNamara et al., [@B71]; Taylor and Bristow, [@B104]) of CVD.

The studies described above confirm that analysis of patients DNA may be useful to understand sympathetic vasodilation mechanism and implication of NO pathway and to create new therapeutical strategies against CVD.

Conclusions {#s2}
===========

The maintenance of myocardial and vascular homeostasis is one of the many diverse physiological functions mediated by NO, a versatile and nearly ubiquitous molecule that plays a key function as a signaling molecule throughout the body. An imbalance in either the production or release of this molecule is correlated to CVD such as hypertension and HF.

It is now evident that the control of endothelium homeostasis and the sympathetic regulation of the vascular tone are the result of a complex crosstalk between NO, β-adrenoreceptors (in particular the β~3~ subtype) and oxidative stress. As an example, recent advances on the β~1~-selective antagonist nebivolol remarked the importance of NO bioavailability in the maintenance of myocardial and vascular homeostasis. A scheme representing some of the functions in which the pathway of NO is strongly involved was presented in Figure [1](#F1){ref-type="fig"}.

![**NO is involved in the sympathetic regulation of vascular tone and in the control of endothelium homeostasis.** The main mechanism leading to increased eNOS activity in endothelial cells is calcium-dependent, but phosphorylation at several loci of the NOS proteins has been recognized as an additional pathway to induce both activation and inhibition of eNOS activity. NO diffuses to vascular smooth muscle and produces relaxation by stimulating sGC to increase the levels of the second messenger cGMP. Vascular endothelial cells might also express β-adrenoceptors, thus supporting the hypothesis that the endothelium might control or facilitate β-adrenergic effects on the vessels. Acute β-adrenergic activation caused by β-adrenoceptor agonists stimulates eNOS activity and could increase release of endothelial NO. Permanently high catecholamine levels could lead to overactivation of β-adrenoceptors, increasing eNOS activity and expression. This condition may lead to the uncoupling of eNOS, which produces O~2−~ and ONOO^−^ (ROS). An unbalanced production of NO and O~2−~ is responsible for the formation of ONOO^−^, thus provoking vascular dysfunction. Several stimuli, such as oscillatory shear stress, hyperglycemia and lipid peroxidation could cause impairment in the NADPH oxidase system that, in turn, produces accumulation of ROS and reduction of NO content. Nebivolol, a β-blocker with a distinctive profile, combines the properties of a β~1~-AR antagonist and β~3~-AR agonist. Nebivolol could enhance NO release via stimulation of β~3~-ARs and, thanks to its antioxidant activity, it prevents the detrimental effect on NO bioavailability associated to oxidative stress. Life-style changes and non-pharmacological interventions (such as caloric restriction and exercise training) show a positive role on the maintenance of cardiovascular homeostasis, at least in part, by inducing the activation of eNOS and increasing NO bioavailability. Abbreviations: AR, adrenoreceptor; cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; GTP, guanosine 5′-triphosphate; NADPH, reduced nicotinamide adenine dinucleotide phosphate; NO, nitric oxide; O^−^~2~, superoxide; ONOO^−^, peroxynitrite; P, phosphoryl; ROS, reactive oxygen species; sGC, soluble guanylate cyclase. ↓ Activation; ⊥ inhibition.](fphys-04-00321-g0001){#F1}

It is our opinion that the effective clinical/therapeutic management of CVD requires the understanding of the molecular determinants responsible for this crosstalk to identify new targets and develop new clinical strategies.
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